



# INTERNATIONAL SYMPOSIUM

Novel drugs for Graves' orbitopathy:  
EUGOGO in clinical trials  
and translational research

**HOTEL SPLENDID - BAVENO**  
**LAGO MAGGIORE**  
**APRIL 3-5, 2025**



**FINAL PROGRAM**

# INTERNATIONAL SYMPOSIUM

## Novel drugs for Graves' orbitopathy: EUGOGO in clinical trials and translational research

---

### FINAL PROGRAM

**Thursday, Apr 3<sup>rd</sup>**

- |         |  |
|---------|--|
| 1.00 pm | Registration   |
| 1.45 pm | Opening remarks: Mario Salvi, Ilaria Muller, Anja Eckstein   |
| 2.00 pm | <p>Discussion of survey - suitability of EUGOGO centers for RCTs</p> <p><b>Chairs:</b> <i>Anja Eckstein (Essen) &amp; Maria Laura Tanda (Varese)</i></p> <p>Hints on the new R3 GCP focused on the role of the PI and Sponsor</p> <p><i>Francesca Degl'Innocenti (Clinical Trial Center, Milan)</i></p> <p>Self-promoted clinical trials: main topics on the design and management</p> <p><i>Giuliana Fusetti (Clinical Trial Center, Milan)</i></p> <p>Requirements for participating centers: dedicated personnel, equipment, certificates (i.e. GCP)</p> <p><i>Benedetta Montacchini (Milan)</i></p> <p>Data collection during clinical trials</p> <p><i>Beatrice Dazzi (Milan)</i></p> |
| 3.30 pm | <i>Coffee break</i>  |
| 3.45 pm | <p>Reports on ongoing Clinical Trials and experience with therapeutics:</p> <p>Teprotumumab: Efficacy of teprotumumab on medical and surgical resistant DON</p> <p><i>Juliette Abeillon (Lyon)</i></p> <p>Batoclimab: Effectiveness in GO and Graves' disease</p> <p><i>Alessandro Antonelli (Pisa)</i></p>  |

# INTERNATIONAL SYMPOSIUM

## Novel drugs for Graves' orbitopathy: EUGOGO in clinical trials and translational research

---

Linsitinib: Report of preliminary results of LIDS trial

*Anja Eckstein (Essen)*

Veligrotug : Report of preliminary results  
of THRIVE 1-2 studies

*Claire Feeney (London)*

Tocilizumab: Efficacy and Safety of Tocilizumab in Patients  
With Active Moderate-to-Severe Corticosteroid-Resistant  
TED

*Tomasz Bednarczuk (Warsaw),*

*Milos Zarkovic (Belgrade)*

The TOGO study: TCZ vs steroids

*Erica Crivicich (Milan)*

Satralizumab: The Satrago Study

*Michele Marinò (Pisa)*

Lonigutumab (Longitude 2)

*TBD*

Efgartigimod

*Muhittin Yalcin (Ankara)*

K1-70

*Jane Sanders (Cardiff)*

7.00 pm

Social Get together

# INTERNATIONAL SYMPOSIUM

## Novel drugs for Graves' orbitopathy: EUGOGO in clinical trials and translational research

---

Friday, Apr 4<sup>th</sup>

- 9.00 am      **Round Table:** Investigator initiated trials: how can we assess capacity of EUGOGO centers  
**Chair:** *A.Eckstein (Essen)*  
**Speakers:** *M. Marinò (Pisa), M. Salvi (Milan), T. Bednarczyk (Warsaw), N. Currò (Milan), S. Pitz (Frankfurt), L. Du Pasquier (Paris), J. Abeillon (Lyon)*
- 10.30 am      *Coffee break*
- 10.40 am      New interventional trials  
*C. Feeney (London)*      Thyroidectomy/ RAI - VL  
Radiological Activity Score  
- DWI MRI for GO  
*G. Sundar (Singapore)*      Imaging at diagnosis  
vs. 24-36 months  
and long term (5-10 yrs)  
*Ilaria Muller (Milano)*      Investigating lymphocytes resident  
within target tissues to personalize  
and optimize GO therapy  
*Michele Marinò (Pisa)*      The Exosome study in GO
- 12.00 pm      Open questions and issues
- 1.00 pm      *Lunch*
- 2.00 pm      Observational / epidemiological trials  
**Chairs:** *Cristina Burlacu (Brussels), Milos Zarkovic (Belgrade)*  
Results of a French multicentric survey conducted with the  
French patient organization "Vivre sans Thyroïde"  
*J. Abeillon (Lyon)*  
Survey on the Management of Mild Thyroid Eye Disease  
*T. Bednarczyk (Warsaw), MC Burlacu (Brussels)*

# INTERNATIONAL SYMPOSIUM

## Novel drugs for Graves' orbitopathy: EUGOGO in clinical trials and translational research

---

Ethnic variations at presentation ( see PREGO ) -  
Comparing Caucasian & Afro-Caribbean descent and our  
center with East Asian (Chinese, Japanese, Koreans),  
Southeast Asian (Malays) & South Asians  
(Indians, Bangladeshis, etc)

*G. Sundar (Singapore)*

AI algorithm for prediction and early diagnosis of GO

*Mirco Armenti (Milan)*

3.30 pm

*Coffee break*

3.45 pm

Industry-Academy EU projects (IHI 2025):  
seeking industry partnership with EUGOGO centers

*Marian Ludgate* very brief overview of scheme

*Anja Eckstein (plus EUGOGO colleagues)* WP2:

Patient recruitment, sample collection, establishment of  
database/registry, phone-app development etc

*Monica Marazuela (plus Giulia Masetti and all participants)*

WP3: Algorithm(s) to predict disease outcome/TED  
phenotype based on spectrum of clinical, biochemical and  
immunological analytes

*Ilaria Muller (plus Steph Hannah, Gina Gortz)* WP4:

Autoantibodies – TRAB titre variation within/between  
patients, novel signalling cascades and antigenic targets

*Steph Hanna (plus Monica Marazuela, Ilaria Muller,  
Simon Pearce)* WP5: Antigen-specific T & B cells –  
their location etc

*Gina Gortz (plus Essen colleagues)* WP6:

In vivo model(s) - improvements to how faithfully they mimic  
GD/TED, adaptation to allow effect of therapies  
on reproduction

# INTERNATIONAL SYMPOSIUM

## Novel drugs for Graves' orbitopathy: EUGOGO in clinical trials and translational research

---

*Simon Pearce* WP7: Clinical studies - combined therapy?

*Mario Salvi (plus Monica Marazuela and EUGOGO colleagues)* WP8: The orbit -imaging of TED patients, ex vivo spatial transcriptomics, in vitro OF models

*Giulia Masetti* WP1: Management; WP9: Consolidation & Dissemination; Future EU grant calls  
Industry partners: RSR, Argenx, Merida, Acelyrin, Roche, Lundbeck, Viridian, Amgen

8.00 pm          Networking Dinner

### Saturday, Apr 5<sup>th</sup>

9.00 am          EUGOGO General Assembly and budget approval  
(agenda tbd)

11.00 am          Organization of operational task forces and working groups

11.30 am          AOB and conclusions

**Organizer:**  
*Graves' Orbitopathy Center, Milan, Italy*

**Participants:**  
*EUGOGO members, clinical and research collaborators, scientists*

# INTERNATIONAL SYMPOSIUM

Novel drugs for Graves' orbitopathy:  
EUGOGO in clinical trials and translational research

---

*With unconditional contribution of*



FASI s.r.l.  
Via O. Tommasini 7 | 00162 Roma  
Tel. 06 97605616 | Fax 06 97605650  
v.toti@fasieventi.com | www.fasieventi.com

